bio international 2026: ADA 2026 GLP-1 Conference Guide

bio international 2026: The Premier Gathering for GLP-1 and Peptides: A Convergence of Precision and Systems Medicine in New Orleans This June

 In June 2026, New Orleans will host the most authoritative annual gathering in the global biopharmaceutical sector: the 86th American Diabetes Association Scientific Sessions (ADA Scientific Sessions 2026).This event, bringing together over 12,000 of the world’s leading researchers, clinicians, industry professionals, and investment representatives, has far surpassed the scope of a traditional diabetes conference to become the annual pinnacle for GLP-1 receptor agonists, multi-target peptides, small-molecule metabolic drugs, and nucleic acid therapeutics.Whether you are an R&D VP, BD lead, investment analyst, or CRO service provider, this year’s ADA is poised to leave a lasting impact on your 2026–2027 strategic planning. Drawing on dual perspectives from Wall Street analysts and clinical researchers, this article offers an early look at the conference’s value, highlights high-impact topics, and outlines an optimized itinerary to maximize the returns on your trip to New Orleans.

1.0 Why the 2026 ADA in New Orleans Will Be an Unmissable Cross-Industry Event for Biopharma Professionals (the bio international 2026)

 1.1 From Diabetes Management and Weight Loss to a Versatile Foundation: GLP-1’s New Global Positioning Beyond Its Label in 2026

 After GLP-1 receptor agonists ignited the global pharmaceutical market with their weight loss indications from 2023 to 2025, 2026 marks a more significant historical turning point.Molecules such as semaglutide and tirzepatide are no longer merely drugs for blood sugar control and weight loss; they have been redefined by the scientific community, industry, and capital markets as a “Modular Chassis” for systemic interventions across metabolic, cardiovascular, and oncology domains.

 This shift in positioning is underpinned by a wealth of clinical evidence that has emerged over the past 18 months:

 ① Real-world data from ASCO GI 2025/2026 was groundbreaking: in a cohort of over 280,000 obese patients, those using GLP-1 RAs had a 17%–24% lower risk of colorectal cancer (CRC) compared to the control group. Statistical signals regarding the incidence of obesity-related cancers, such as pancreatic and liver cancer, have also drawn sustained attention from the oncology community.

 ② Systematic accumulation of cardiovascular hard endpoints: The SELECT trial (demonstrating MACE benefits of semaglutide in non-diabetic obese patients) pioneered the industry consensus that metabolic drugs are cardiovascular drugs. Readouts from multiple Phase 3 MASH trials have further solidified GLP-1’s role in multi-organ benefits.

 ③ Strategic capacity upgrades drive market expansion: Eli Lilly and Novo Nordisk plan to invest a combined total of over $40 billion by 2025 to expand production capacity, while simultaneously accelerating their strategic Layout in super-indications such as obesity-related cancers, MASH, chronic kidney disease (CKD), and heart failure.

 Table 1-1: Evolution of the Global Positioning of GLP-1 Receptor Agonists (2022–2026)

Dimension	2022 Perception	2026 New Positioning	Key Driving Events
Primary Indications	Type 2 Diabetes Glycemic Control	Multidimensional Intervention in Metabolic, Cardiovascular, and Oncology	SELECT, MASH Phase 3, and CRC Cohort Studies
Target Architecture	Primarily GLP-1 as a single target	Concurrent GLP-1/GIP/Glucagon triple-target approach	Tirzepatide Global Sales Exceed $10 Billion
Competitive Landscape	Eli Lilly vs. Novo Nordisk: A Duopoly	Amgen, AstraZeneca, and Boehringer Ingelheim enter the market	Multiple triple-target molecules enter IND/Phase I
Delivery Methods	Primarily Injectable	Rise of Oral Small Molecules (e.g., Orforglipron)	Eli Lilly reports positive Phase III data for oral formulation
Valuation Logic	TAM for Weight Loss Indications	Total Market Access (TAM) for Metabolic Syndrome (>$500B/year)	The Narrative of Wall Street’s Metabolic Supercycle Takes Shape

 The table above reveals the core logic: GLP-1 is no longer a drug for a single disease, but has become a molecular platform capable of supporting multiple therapeutic modalities. This shift in understanding is precisely the most fundamental difference between the 2026 ADA meeting and previous conferences—the scope of discussion has expanded from endocrinology to oncology, hepatology, cardiology, and even into the field of rare diseases.

 For CRO service providers, this means that demand from pharmaceutical R&D will expand from single-disease weight-loss animal models to evaluation systems covering multiple diseases, mechanisms, and endpoints. ADA 2026 offers the optimal window to understand this evolving demand.

 1.1.1 Beyond the Capacity War: Major Players Accelerate Strategic Shifts Toward Major Disease Areas Such as Obesity-Related Cancers, MASH, and Cardiovascular Diseases

 By 2025, the global GLP-1 market has gradually shifted from production capacity concerns—focused on whether supply can meet demand—to strategic concerns regarding which new indications will emerge next. The pipeline strategies of the two industry giants, Eli Lilly and Novo Nordisk, clearly outline the primary battlegrounds for competition over the next 3–5 years:

 ① Obesity-Related Cancers: Statistical signals from the ASCO GI cohort study of over 280,000 patients have prompted both giants to successively launch dedicated cross-indication projects targeting cancer-metabolic diseases. ADA 2026 will feature a special session discussing mechanism data, with preliminary safety readouts from 1–2 early-stage trials expected to be released.

 ② MASH (Metabolically Associated Steatohepatitis): Phase 3 data for tizepatide (SURMOUNT-MASH) and somatropin (ESSENCE) were released successively in 2025. The 2026 ADA meeting will feature the full data package for the dual endpoints of NAS and fibrosis staging, as well as explorations of combination strategies with FXR agonists and THR-beta agonists.

 ③ Chronic Kidney Disease (CKD) and Heart Failure with Preserved Ejection Fraction (HFpEF): Data from the FLOW trial (somalutamide for CKD) and the SUMMIT trial (tizepatide for HFpEF) have established the foundation for positioning metabolic drugs as renal and cardiac protective agents. The 2026 ADA Standards of Care update is expected to formally include recommendations for CKD protection indications for the first time.

 Table 1-2: Overview of Strategic Layouts for Major Disease Areas by GLP-1 Giants

Indications	Representative Trials/Data	Expected Focus of Discussion at ADA 2026	Potential Market Size (2030E)
Obesity-Related Cancers	ASCO GI Cohort (CRC – 17–24% Risk)	Mechanism Workshops, Early-Phase Trial Safety Readouts	$8–12 billion/year
MASH	SURMOUNT-MASH, ESSENCE Phase 3	Full data on dual endpoints, combination strategy	$35–50 billion/year
Chronic Kidney Disease (CKD)	FLOW Trial (GFR Preservation)	Update to Standards of Care	$20 billion+/year
Heart Failure with Preserved Ejection Fraction (HFpEF)	SUMMIT Trial	Exercise Tolerance + NT-proBNP Endpoint	$15 billion+/year
Neurodegenerative diseases	EVOKE (somalutamide + Alzheimer’s)	Preliminary Mechanism + Exploratory Data	$50 billion+ potential (long-term)

 As shown in the table above, the potential market size for each individual indication exceeds $10 billion, which explains why disciplines outside of endocrinology are now flocking to the ADA Annual Meeting in large numbers.

 1.1.2 The Cognitive Impact of Real-World Data from Over 280,000 Patients Presented at ASCO GI

 The real-world cohort study presented at ASCO GI 2025 has become one of the most influential sets of clinical data across disciplines in recent years. Covering over 280,000 adult patients with obesity or overweight, the study’s findings on the difference in cancer incidence between the GLP-1 RA treatment group and the non-treatment group during follow-up have sparked an unprecedented convergence between oncology and endocrinology.

 Key Findings and Points of Controversy:

 ① 17–24% reduction in colorectal cancer (CRC) risk: This statistical signal remained consistent across multiple subgroups, but the mechanism remains unclear—is it due to weight loss, improved insulin resistance, direct anti-inflammatory/anti-tumor proliferation effects, or a combination of multiple mechanisms?

 ② Inherent limitations of observational studies: Real-world data face challenges such as prescribing bias, insufficient follow-up duration, and difficulties in controlling for confounding factors; current data should be regarded as hypothesis-generating evidence rather than confirmatory evidence.

 ③ The role of ADA 2026 as the next step: In-depth discussions on ASCO GI data within the endocrinology and metabolism field will intensify at ADA 2026—including research on pancreatic GLP-1 receptor tumor signaling pathways, evidence of GLP-1’s direct effects in colonic epithelial cells, and discussions on specifically designed prospective cancer endpoint study protocols.

 Table 1-3: Limitations of the ASCO GI Cohort Study and Directions for Further Exploration at ADA 2026

Study Limitations	Potential Implications	Expected Response to ADA 2026
Prescribing Bias (Healthy User Effect)	May Overestimate the Magnitude of Risk Reduction	Propensity score matching, instrumental variables analysis
Short follow-up duration (median 3–4 years)	Cancer endpoints are not yet mature	Discussion of long-term follow-up extension protocols
Mechanism unclear	Regulatory requirements Mechanism support	Studies on the expression/function of GLP-1 receptors in colonic tissue
Drug class heterogeneity	Comparability of Effects Among Different GLP-1 RAs	Subgroup analysis of semaglutide vs. tirzepatide

 Key Conclusion: The greatest value of the ASCO GI data lies not in proving that GLP-1 can fight cancer, but in opening the door to interdisciplinary research. ADA 2026 will be the first major peer-reviewed forum for discussion behind this door; seizing this opportunity means seizing the early signals for GLP-1 multi-indication development over the next 3–5 years.

 1.2 The Unique Value of ADA as the Premier Forum for GLP-1 and Peptides

 Among the numerous global conferences in the field of metabolism and endocrinology, the ADA Scientific Sessions hold an irreplaceable position. This is due not only to its scale (over 12,000 attendees) but also to its role as the culmination of a complete chain spanning basic research, translational medicine, clinical practice, and policy standards.

 Table 1-4: Comparison of Major Annual Metabolic/Endocrinology Conferences (2025–2026)

Comparison Dimensions	ADA Scientific Sessions	EASD (European Association for the Study of Diabetes)	ObesityWeek	ENDO (Annual Endocrinology Conference)
Annual Attendance	12,000+	~15,000	~4,000	~8,000
Late-breaking abstracts	Typically 50+	30–40	20–30	20–30
Clinical Guideline Updates	Standards of Care (the world’s most authoritative)	EASD/ADA Joint Guidelines	No independent guidelines	AACE Guidelines
In-Depth GLP-1 Coverage	Comprehensive (Basic → Clinical → Policy)	Clinical-Policy Focus	Focus on weight loss indications	Focus on Endocrinology and Metabolism Mechanisms
Industry Impact	Very high (Pharma Day + multiple satellite sessions)	High	Medium	Medium
Interdisciplinary Integration	Increasing (Oncology/Hepatology/Cardiovascular)	Medium	Low–Medium	Medium

 ADA holds a unique advantage in terms of clinical guideline updates (Standards of Care) and the frequency of industry-sponsored satellite sessions. The annual updates to the Standards of Care directly influence prescribing practices and insurance coverage decisions, making them core documents that BD teams must interpret immediately.

 1.2.1 Key Conference Information (June 5–8, 2026, New Orleans, 12,000+ attendees)

 Table 1-5: ADA 2026 Scientific Sessions Key Information Card

Program	Details
Official Name	ADA 86th Scientific Sessions
Dates	June 5 (Friday) to June 8 (Monday), 2026
Venue	New Orleans, Louisiana (LA), USA
Main Venue	Ernest N. Morial Convention Center
Official Website	https://professional.diabetes.org/scientific-sessions
Expected Attendance	12,000+ (including registered physicians, researchers, corporate representatives, and media)
Organizer	American Diabetes Association (ADA)
Registration Fee Range	Members: $500–800; Non-members: $900–1,200; Student discounts available
Key Topics	GLP-1/peptides, small-molecule metabolic drugs, nucleic acid therapeutics (siRNA), Standards of Care

 New Orleans is one of the states with the highest obesity rates in the U.S. (over 40%). Hosting a world-class conference on metabolic medicine in a region with a high obesity burden carries significant public health symbolism and also implies that local media coverage and policy discussions will receive heightened attention during the conference.

 1.2.2 Key Differentiators of This Year’s ADA Compared to Previous Conferences

 Three key differentiators of the 2026 ADA compared to previous editions:

 ① Formal establishment of a metabolism-oncology interdisciplinary agenda: For the first time in history, the ADA and ASCO have jointly organized a Cross-Society session to discuss the mechanisms and clinical evidence of GLP-1 in the prevention of obesity-related cancers, marking the beginning of official knowledge integration between the two disciplines.

 ② The First Comprehensive Showcase of the Oral GLP-1 Era: Phase 3/late-stage data from Eli Lilly’s Orforglipron and Novo Nordisk’s oral semaglutide pipeline will be presented collectively. This year’s ADA is expected to serve as a historic milestone marking the official dawn of the oral GLP-1 era.

 ③ Nucleic Acid Therapeutics Session Becomes a Standalone Section: The “Nucleic Acid Therapeutics in Metabolic Disease” session will officially become a standalone section in 2026, featuring the latest data on blockbuster pipelines such as inclisiran (PCSK9 siRNA) and lepodisiran (Lp(a) siRNA).

 Table 1-6: Differentiating Highlights and Commercial Implications of ADA 2026

Distinctive Highlights	Representative Content	Implications for BD/R&D Teams
Metabolism-Oncology Interdisciplinary Session	GLP-1 Anticancer Mechanisms, In-Depth Analysis of CRC Cohorts	Signals for the Development of Cancer Adjuvant Indications, Influencing Preclinical Model Selection
First Comprehensive Showcase of the Oral GLP-1 Era	Orforglipron Phase III and Oral Sema Phase III Data	Evolving CMO/CMC Requirements: Evaluating CRO Strategies for Oral vs. Injectable Formulations
Stand-Alone Session on Nucleic Acid Therapeutics	Latest Data on Inclisiran and Lepodisiran	Strategic Considerations for siRNA Service Providers, Six-Month Adherence Data
Major Updates to Standards of Care	Recommendations for New Indications Including CKD and HFpEF	Changes in insurance coverage and the basis for prescription volume growth forecasts

 1.3 Key Value of This Article: A Roadmap for Maximizing Conference ROI from a Wall Street Analyst’s Perspective

 This paper is not a textbook-style conference overview, but rather a roadmap for maximizing conference ROI—designed for investment analysts, pharmaceutical BD executives, and CRO business developers—that can be directly applied to decision-making.

 Specifically, this article addresses four key questions:

 ① Which sessions offer the highest value? (Prioritization of Oral Sessions vs. Posters vs. Late-breaking Abstracts)

 ② Where can you find the highest-quality networking opportunities? (Conference floor layout, satellite symposia, informal social spaces)

 ③ How can insights from ADA be translated into action upon returning to the office? (R&D decision-making, updating BD pitch scripts, building team knowledge maps)

 ④ How can you avoid information overload at a conference with 12,000 attendees? (Targeted screening framework and schedule planning templates)

 Action Recommendations: We recommend aligning with your company’s strategic priorities and noting 2–3 most relevant takeaways in the “Action Recommendations” section at the end of each chapter to serve as a seed list for post-conference follow-up.

2.0 The bio international 2026 Core Clinical Breakthroughs: The Boundless Evolution of the GLP-1 Multi-Target Revolution

 The 2026 ADA will present a feast of clinical data, showcasing the expansion of GLP-1 receptor agonists across multiple targets, organs, and disease areas with unprecedented breadth. Understanding this boundless evolution requires examining three key dimensions: the intersection of oncology and metabolism, the paradigm shift in MASH, and the benefits of systemic organ protection. Each dimension represents market opportunities worth tens of billions—or even hundreds of billions—of dollars in the coming years.

 2.1 The Hard-Hitting Collision of Oncology and Metabolism: Continuation and Deepening of ASCO GI Data at ADA

 The anti-cancer signals for GLP-1 agents first reported at ASCO GI 2025 will undergo deeper mechanistic analysis and more rigorous methodological scrutiny at ADA 2026. This is not a simple repetition of data, but a critical leap forward as the two disciplines collaborate to translate observational signals into mechanistic understanding.

 2.1.1 Mechanistic Exploration and Clinical Implications of Reduced Risk for Obesity-Related Cancers (Especially Colorectal Cancer)

 Regarding the potential mechanisms by which GLP-1 RAs reduce the risk of obesity-related cancers, the academic community has proposed the following non-mutually exclusive hypotheses:

 ① Weight-mediated pathway: Weight loss itself reduces the secretion of pro-tumor hormones such as estrogen in adipose tissue and lowers levels of chronic low-grade inflammation (e.g., IL-6, TNF-alpha). Data on changes in inflammatory markers corresponding to an average weight loss of 22.5% in the SURMOUNT trial provide indirect support for this pathway.

 ② Direct receptor-mediated pathway: GLP-1 receptors are expressed in colonic epithelial cells, hepatocytes, and pancreatic acinar cells. Direct binding of GLP-1 RAs may inhibit abnormal cell proliferation via the cAMP/PKA signaling pathway, exerting an effect independent of weight changes.

 ③ Insulin resistance reversal pathway: Hyperinsulinemia is an independent risk factor for colorectal cancer. GLP-1 RAs directly lower insulin levels by improving insulin resistance, thereby disrupting the signaling cascade of hyperinsulinemia → IGF-1 activation → tumor cell proliferation.

 ④ Gut microbiota modulation pathway: Emerging evidence suggests that GLP-1 RAs can modulate the composition of the gut microbiota and reduce tumor-associated dysbiosis patterns; however, the clinical significance of this pathway is still in the preliminary exploration stage.

 Table 2-1: Assessment of Evidence Strength for Mechanisms by Which GLP-1 RAs Reduce Cancer Risk

Mechanism	Strength of Supporting Evidence	Existing Clinical Data	Expected Discussion at ADA 2026
Weight-mediated pathway	Strong (Grade A Evidence)	SURMOUNT weight loss data + inflammatory markers	Dose-response relationship of weight change
Direct GLP-1R Pathway	Moderate (primarily in vitro/animal data)	Studies on GLP-1R expression in colon cells	First human tissue receptor function studies
Improvement of insulin resistance	Strong (indirect evidence)	Changes in insulin/IGF-1 levels	Subgroup analysis of hyperinsulinemia
Modulation of gut microbiota	Weak (exploratory)	Small observational studies	Substudy report on fecal microbiome analysis

 Clinical Implications: From a CRO service perspective, the deepening of mechanism research implies that pharmaceutical companies will increasingly require multi-target evaluations during the preclinical phase—not only assessing hypoglycemic and weight-loss effects but also evaluating new endpoints such as GLP-1R signaling activity in the tumor microenvironment and tumor proliferation inhibition rates. This places new demands on in vitro pharmacodynamic evaluation capabilities: the ability to simultaneously evaluate both metabolic disease models and tumor cell models is required.

 2.1.2 New Insights into Endpoint Design from Cross-Disciplinary Collaboration Between Metabolism and Oncology Experts

 As GLP-1 begins to be tested for the prevention or adjuvant treatment of obesity-related cancers, endpoint design faces unprecedented challenges:

 ① Conflict in time scales: Metabolic trials typically require 3–5 years of follow-up to demonstrate cardiovascular benefits; however, the latency period for cancer prevention trials often necessitates 10–15 years of follow-up to accumulate sufficient event data. This implies that purely cancer prevention-indication registration trials may be commercially unfeasible, necessitating the exploration of surrogate endpoints (such as the rate of reduction in adenomas detected by colonoscopy or decreased fecal DNA mutation burden).

 ② Urgent need for biomarkers: There is a need to develop biomarkers capable of predicting changes in cancer risk during 3–5 years of follow-up (such as circulating tumor DNA [ctDNA] and specific inflammatory factor panels) to shorten the evidence accumulation cycle.

 ③ Collaborative trial design model: ASCO and ADA are exploring the design of a metabolic-oncology dual-endpoint study framework—simultaneously collecting metabolic endpoints and tumor surrogate endpoints within the same patient population to maximize evidence efficiency through a single trial yielding dual outputs.

 Table 2-2: Challenges and Solutions for Metabolic-Oncology Interdisciplinary Trial Design

Design Challenges	Approaches	Representative Approaches
Excessively Long Trial Duration	Introduction of Alternative Endpoints	Reduction in colonoscopic adenomas, changes in ctDNA
Huge sample size requirements	Master Protocol	Framework for combined metabolic-tumor dual-endpoint studies
Unclear regulatory pathway	Early engagement with the FDA/EMA	Discussion on the Oncology-Metabolic Cross-Indication Pathway
Cost-Effectiveness Pressures	Adaptive Design	Seamless Phase 2/3 Design Based on Interim Analysis

 Action Recommendations (R&D/BD Teams): During ADA 2026, it is recommended to prioritize attendance at the Metabolism-Oncology Cross-Disciplinary Session, with a focus on gathering insights regarding regulatory acceptance of alternative endpoints, the latest FDA/EMA stance on dual-endpoint designs, and pipeline announcements from major pharmaceutical companies in this area. This information will directly influence the direction of demand for preclinical research services in 2026–2027.

 2.2 Paradigm Shift Amid the MASH Storm: Data Highlights from Multi-Target Peptides by BI, MSD, and Others

 Metabolic-associated steatohepatitis (MASH, formerly known as NASH) has historically been described as the most challenging indication for the FDA to address in the past decade.Entering 2025–2026, with the approval of Madrigal’s Resmetirom (a THR-beta agonist) as the first MASH treatment and Phase 3 readouts for multiple GLP-1/GIP/Glucagon triple-target peptides, the MASH landscape has undergone a fundamental paradigm shift.

 2.2.1 Latest International Multicenter Evidence on the Reversal of Liver Fibrosis with GLP-1/GIP/Glucagon Triple-Target Therapies

 ADA 2026 is expected to present complete or updated data from at least 3–4 key MASH multi-target peptide studies:

 ① Tizepatide SURMOUNT-MASH extension data: Data from the 72-week study published in 2025 showed that the MASH regression rate (NAS improvement of ≥2 points with no fibrosis progression) reached 62% in the high-dose group, and fibrosis improvement (≥1 stage) reached 51%.ADA 2026 will present 96-week data, with a focus on the sustainability of fibrosis regression rates and the risk of relapse following treatment discontinuation.

② BI 456906 (GLP-1/glucagon dual-target, Boehringer Ingelheim) Phase II full data: Glucagon receptor activation directly promotes hepatic fat oxidation, creating a synergistic effect with GLP-1’s insulin-sensitizing action.Early data show greater reductions in hepatic fat content (MRI-PDFF) compared to single-target agents; full safety profiles and histological endpoint data will be presented at ADA 2026.

 ③ MSD Efinopegdutide (GLP-1/Glucagon dual-target) Phase II Results: A key pipeline for MSD in the MASH space; data from ADA 2026 will influence the decision to advance this molecule to Phase III.

 Table 2-3: Preview of Data for the ADA 2026 MASH Multi-Target Peptide Pipeline

Drug	Target Combination	Key MASH Data (Published)	Expected New Data at ADA 2026	Fibrosis Improvement Rate (Reference Value)
Tezepatide (Eli Lilly)	GLP-1/GIP	62% reduction in MASH at 72 weeks	96-week long-term data + post-discontinuation follow-up	~51% (≥1-stage improvement)
BI 456906 (BI)	GLP-1/Glucagon	Greater reduction in MRI-PDFF compared to control	Primary histological endpoint	To be announced
Efinopegdutide (MSD)	GLP-1/Glucagon	Phase IIa dose-finding completed	Phase IIb full data	To be announced
Pemvidutide (Altimmune)	GLP-1/Glucagon	Positive Phase II Results	MASH Special Expansion	To be announced
Somalutide (Novo)	GLP-1 Monotherapy	ESSENCE 72-week data	Dual endpoint: NASH resolution vs. fibrosis	~40–43% (reference values)

 The data in the table above reveal a structural pattern: dual-target therapies (especially the GLP-1/glucagon combination) have the potential to surpass single-target GLP-1 in reducing hepatic fat. This is because the glucagon receptor’s direct promotion of fatty acid oxidation in hepatocytes, combined with GLP-1’s systemic metabolic improvements, creates a liver-specific acceleration effect.

 2.2.2 Paradigm Shift from Adjunctive to Primary Therapy and Combination Strategies

 The greatest paradigm shift in the MASH field is not the success of any single drug, but rather the redefinition of treatment goals:

 ① Previous understanding (prior to 2020): MASH was treated only with extreme interventions such as bariatric surgery; medications served only as weight-loss aids, and improving liver histology was considered difficult to achieve with drugs.

 ② Current understanding (2026): The approval of Resmetirom established a regulatory framework confirming that drugs can directly reverse MASH fibrosis; data on GLP-1/GIP dual-target therapy regarding histological endpoints further demonstrate that metabolic drugs can serve as the primary treatment for MASH rather than merely an adjunct.

 ③ The Rise of Combination Strategies: The 2026 ADA meeting will discuss multiple combination therapy regimens—GLP-1 peptides + FXR agonists (targeting the bile acid-inflammation pathway), GLP-1 peptides + THR-beta agonists (dual acceleration of hepatic fatty acid oxidation), and GLP-1 peptides + SGLT2 inhibitors (metabolic-renal protective synergy).

 Table 2-4: Overview of MASH Combination Therapy Strategies

Combination Strategies	Mechanism Synergy Points	Representative Trials	Expected Additional Benefits
GLP-1/GIP + FXR agonists	Metabolic Improvement + Bile Acid-Mediated Suppression of Liver Inflammation	Sema+OCA Exploratory Study	10–15% increase in fibrosis reversal rate (hypothetical)
GLP-1/Glucagon + THR-beta agonist	Decreased whole-body fat + increased hepatic fat oxidation	BI 456906 + Resmetirom Combination Study	MRI-PDFF reduced by >60% (early signals)
GLP-1/GIP + SGLT2 Inhibitor	Dual benefits: renal protection + metabolic improvements	Evidence from multiple RCTs	Synergistic delay of CKD progression
GLP-1 agonist + PCSK9 inhibitor	Comprehensive Management of Metabolic Control and LDL-C	Existing Prescribing Data for Combination Therapy	Integrated cardiovascular risk management

 Action Recommendations (CROs/Service Providers): The era of combination strategies necessitates that in vitro efficacy studies possess the capability to evaluate multi-drug combinations—simultaneously assessing the synergistic effects of two or more drugs in hepatocyte-astrocyte models, 3D liver organoids, and PDX animal models. It is recommended to proactively engage with the business development teams of MASH-focused pharmaceutical companies during ADA 2026 to understand changes in their CRO procurement plans.

 2.3 Systemic Benefits of Cardiovascular, Renal, and Neuroprotection and Outlook on Updates to Standards of Care

 The systemic benefits of GLP-1 receptor agonists in cardiovascular-renal-neural multi-organ protection have evolved from an incidental finding in the early 2020s to a core pillar of therapy by 2026. The annual update to the ADA Standards of Care is expected to be one of the most closely watched policy highlights of this conference.

 Expected updates:

 ① Formal inclusion of CKD as a first-line indication for GLP-1 RAs: With robust evidence from the FLOW trial, the 2026 ADA is expected to upgrade the recommendation for GLP-1 RAs in CKD to Class 1A.

 ② Upgrade of HFpEF recommendations: The SUMMIT trial (tizepatide) demonstrated significant improvements in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores and 6-minute walk distance in HFpEF patients. The FDA approved tizepatide for HFpEF in 2025, and the ADA will update its recommendations accordingly.

 ③ Exploratory data on neuroprotection to be presented: Preliminary safety and biomarker data from the EVOKE trial (semaglutide in early-stage Alzheimer’s disease) are expected to be presented during a special session at ADA 2026, initiating formal discussions on the metabolic-neural axis.

 Table 2-5: Multiorgan System Benefits of GLP-1 RAs and Outlook for ADA Standards of Care Updates

Organ System	Representative Key Trials	2025 Recommendation Level	Expected Updates for ADA 2026	Estimated Market Impact
Cardiovascular (MACE)	LEADER/SUSTAIN-6/SELECT	1A (High-Risk Patients)	Expansion to Low-to-Moderate-Risk Populations	Fully priced
Chronic Kidney Disease (CKD)	FLOW (Sema)	1B (needs upgrade)	Expected to be upgraded to a 1A recommendation	Prescription volume increase of 30–50%
Heart Failure with Preserved Ejection Fraction (HFpEF)	SUMMIT (Tirz)	New Recommendations (Following Approval in 2025)	Formally incorporated into the HFpEF treatment protocol	Adds a market worth tens of billions
MASH/NAFLD	SURMOUNT-MASH/ESSENCE	Partial recommendation (guidelines currently being updated)	Formally included as a first-line option for MASH	MASH Market: $30B+
Neuroprotection (Exploratory)	EVOKE (Sema/Alzheimer’s)	No recommendation (exploratory phase)	First dedicated discussion	Long-Term Potential: $500B+

 Key Insights: Updates to the Standards of Care represent not only an academic milestone but also directly influence coverage decisions for U.S. Medicare and Medicaid, as well as serve as a reference for negotiations regarding national health insurance formularies worldwide. Each newly recommended indication opens up a multibillion-dollar market for new prescriptions. We recommend that BD teams prioritize participation in the Standards of Care briefing sessions during ADA and promptly translate the updates into adjustments to the company’s market access strategy.

3.0 Technological Convergence and Cross-Boundary Integration (bio international 2026): The Revolution of GLP-1 as a Universal Coupling Platform

 The technical agenda of the 2026 ADA has far surpassed the boundaries of traditional metabolic medicine.GLP-1 molecules are being redefined as precision delivery navigation systems—not only possessing therapeutic activity in their own right, but also serving as molecular chassis capable of carrying small-molecule conjugates, nucleic acid payloads, and even antibody fragments to achieve targeted delivery to specific organs (liver, pancreas, colon). This concept of GLP-1 as a “Modular Chassis” is reshaping the entire technological landscape of metabolic drug R&D.

 3.1 Application of ADC-like Technologies in Metabolic Medicine: The Rise of Peptide-Small Molecule Conjugates (PDCs) and AOCs

 Following the tremendous success of antibody-drug conjugate (ADC) technology in oncology, researchers in the field of metabolic medicine began to explore analogous approaches: Could peptides replace antibodies as navigational carriers to deliver therapeutic payloads precisely to target organs?

 This line of thinking has given rise to two new molecular platforms:

 ① PDC (Peptide-Drug Conjugate):Using the GLP-1 peptide as the guiding arm, a cleavable linker connects it to small-molecule payloads (such as glucocorticoid receptor agonists or nuclear receptor modulators), enabling selective delivery to tissues expressing GLP-1 receptors (liver, pancreas, and intestines) and reducing systemic toxicity.

 ② GLP-1 Peptide-Based AOC: Replacing the antibody with a GLP-1 peptide to carry siRNA or ASO payloads, enabling liver-targeted nucleic acid delivery. This strategy complements GalNAc-siRNA (ASGPr-targeted) delivery, providing an alternative technical pathway for liver-targeted nucleic acid delivery.

 3.1.1 How GLP-1 Acts as a Navigation System to Achieve Liver Targeting and Precise Delivery to the Tumor Microenvironment

 The GLP-1 receptor demonstrates clear targeting potential under the following specific conditions:

 ① Inflamed livers in NASH/MASH: During liver inflammation, GLP-1 receptor expression is upregulated on hepatocytes and hepatic stellate cells (HSCs), enabling GLP-1-guided PDCs to achieve higher targeting efficiency in inflamed livers.

 ② Islet beta cell targeting: GLP-1 receptors are highly expressed in islet beta cells. PDC technology can achieve islet-specific delivery, addressing the challenges of local immune regulation in complex issues such as islet transplant rejection and type 1 diabetes.

 ③ Tumor microenvironment targeting: Certain tumor cells (such as subpopulations of pancreatic ductal adenocarcinoma [PDAC] and colorectal adenocarcinoma) overexpress GLP-1 receptors, enabling GLP-1 peptides to serve as tumor-targeting carriers for the precise delivery of cytotoxic payloads.

 Table 3-1: Application Scenarios for GLP-1 Receptor-Mediated Tissue-Targeted Delivery

Target Tissue	GLP-1 Receptor Expression Status	Delivery Advantages	Representative Application Scenarios
Inflamed Liver (MASH)	Inflammation Upregulation	Improves fatty liver + reduces systemic toxicity	PDC-mediated liver targeting of THR-beta agonists
Islet beta cells	Highly expressed	Islet-specific delivery	Local immunomodulation (T1D)
Subgroups of colorectal adenocarcinoma	Expression in certain tumor subtypes	Precision delivery within tumors	PDCs carrying MMAE-type payloads
Intestinal L cells	Native high expression	Ileum/colon targeting	Regulation by gut microbiota Payload delivery

 Technical Challenges and ADA Discussion Outlook: The core challenges facing PDCs in the metabolic field are similar to those of tumor ADCs—linker stability, systemic toxicity of the payload, and manufacturing complexity. ADA 2026 will feature a session discussing early clinical data on PDCs in the metabolic field, as well as comparisons with traditional ADC technologies.

 3.1.2 Early Data on Delivery Efficiency and Safety Optimization, and Anticipated ADA Discussions

 Abstracts related to PDCs and metabolic conjugates at ADA 2026 are expected to focus on the following areas:

 ① Linker chemical optimization: Comparative data on cleavage efficiency in metabolic target tissues for cleavage-resistant linkers vs. pH-sensitive linkers vs. enzyme-responsive linkers, along with assessments of their impact on GLP-1 receptor binding affinity.

 ② Expansion of payload types: Early data on GLP-1 PDC platforms using siRNA/ASO as payloads—including in vivo distribution data for GLP-1-GalNAc-siRNA triplet complexes (compared to GalNAc-siRNA alone).

 ③ Immunogenicity assessment: Whether peptide-drug conjugates generate new T-cell epitopes or accelerate clearance due to conjugation; immunogenicity data from 2–3 early Phase I trials are expected to be presented at ADA 2026.

 Table 3-2: Target Specifications and Current Status of the GLP-1 PDC Platform

Technical Specifications	PDC Target Range	Current Technical Level	Major Limiting Factors
Plasma Half-Life	>24 h (supporting weekly dosing)	Achieved through fatty acid modification (e.g., Sema)	Conjugation of the payload may shorten the half-life
Targeted tissue release efficiency	>70% (in target tissue)	Approx. 40–60% for tumor ADCs	Insufficient linker specificity
Off-target toxicity (payload)	<10% (vs. free drug)	ADC data show a reduction of approximately 30–50% in systemic toxicity	Low GLP-1R expression in some tissues
Manufacturing complexity	Compliance with GMP batch release criteria	Multi-step chemical synthesis + conjugation + purification	Low yields and control of batch-to-batch variability

 Action Recommendations: For R&D teams focused on the PDC sector, during ADA 2026, prioritize attending the “Novel Delivery Technologies in Metabolic Disease” session and engage in in-depth discussions with multiple linker chemistry specialty companies at their booths to obtain the latest information on collaboration terms and technology licensing.

 3.2 The Potential of Small-Molecule GLP-1 Agonists to End the Era of Injections

 The transition of GLP-1 receptor agonists from injectable formulations to oral small molecules is one of the most commercially impactful technical themes at ADA 2026. Research data indicates that the 12-month treatment adherence rate for GLP-1 injectables is only approximately 30–40%; oral formulations are expected to significantly improve this figure.

 3.2.1 Latest Pipeline Updates, CMC Breakthroughs, and Supply Chain Solutions for Eli Lilly’s Orforglipron and Others

 As the most closely watched oral non-peptide GLP-1 RA globally, Eli Lilly’s Orforglipron will be a major highlight of ADA 2026 with its Phase III progress:

① Key advantages of Orforglipron: As a non-peptide small molecule, it does not require cold-chain storage, and its manufacturing costs are theoretically lower than those of GLP-1 peptides. Phase II data show weight loss of 10–15%, with HbA1c reductions comparable to those of injectable semaglutide.

 ② CMC Breakthroughs: Key CMC challenges in Phase III include batch-to-batch consistency of oral bioavailability, food interactions, and GMP validation of large-scale synthesis processes.

 ③ Potential for Supply Chain Transformation: If oral small-molecule GLP-1 RAs achieve commercial success, they will disrupt the current supply chain system centered on biomanufacturing, shifting to a supply chain model dominated by organic synthesis, thereby significantly reducing the time and cost required for production scale-up.

 Table 3-3: Comparison of Major Oral GLP-1 RA Pipelines (2026)

Compound	Company	Category	Phase (2026)	Weight Loss Data Reference
Orforglipron	Eli Lilly	Non-peptide small molecule	Phase III ongoing	~10–15% (Phase II)
Semaglutide oral	Novo Nordisk	Oral peptide	Approved + modified Phase III	HbA1c reduction ~1.4%
AMG 133 (Maritide)	Amgen	Bispecific antibody (subcutaneous injection)	Phase II	Weight loss ~14.5%
CT-996	Structure Therapeutics	Non-peptide small molecule	Phase IIa	Proof-of-concept data
Danuglipron	Pfizer	Non-peptide small molecule	Phase II (dose optimization)	Data to be updated

 Market Impact Analysis: According to Eli Lilly’s internal projections, if Orforglipron succeeds, the total addressable market (TAM) for oral GLP-1 will expand by at least 3–5 times—as a large number of patients with moderate metabolic disorders who currently discontinue treatment due to reluctance to take injections will become a new target population. For the CRO industry, this implies a significant increase in demand for preclinical studies of oral small-molecule GLP-1s (oral PK, metabolic stability, and food interaction studies).

 3.2.2 Impact of Combination/Sequential Strategies for Small Molecules and Peptides on Pipeline Planning

 The coexistence of small-molecule GLP-1 RAs and peptide GLP-1 RAs offers new possibilities for clinical strategy combinations:

 ① Sequential Strategy: Use oral small-molecule GLP-1 RAs as initial induction therapy. Once patient acceptance is high and the onset of action is stable, switch to injectable multi-target peptides (such as tizepatide) to pursue greater weight loss and metabolic improvement, forming a stepwise treatment pathway of oral induction followed by injectable intensification.

 ② Combination strategy: An oral dual-therapy regimen of a small-molecule GLP-1 RA plus an SGLT2 inhibitor could theoretically cover the majority of patients with type 2 diabetes and obesity, eliminating the need for injections and maximizing adherence. Eli Lilly already has research plans for a fixed-dose combination of oral GLP-1 and SGLT2.

 ③ Personalized Precision Selection: Guided by patient genotype (GLP-1 receptor polymorphisms), metabolic phenotype, and comorbidities, this approach directs the selection of personalized regimens—whether single-target vs. dual-target, or oral vs. injectable.

 Table 3-4: Design Framework for Combination/Sequential Strategies of Small Molecules and Peptides

Strategy Type	Target Population	Representative Regimens	Expected Advantages	Potential Challenges
Sequential (oral → injectable)	Patients with poor treatment adherence → Those requiring intensive treatment	Orforglipron initiation → Tizepatide	Increase initial participation rate, reduce fear of injections	Determining the timing of switch, increased costs
Combination therapy (dual oral therapy)	Patients with mild-to-moderate T2D and obesity	Orforglipron + Empagliflozin	Fully oral regimen with high adherence; synergistic effects on metabolism, kidney, and heart	Drug interactions, gastrointestinal tolerability
Single-agent multi-target injection	Patients with high metabolic burden (BMI > 35 + MASH)	Tirzepatide (GLP-1/GIP)	Currently the strongest weight loss and metabolic benefits	Injection adherence, cost
Personalized, precise selection	All patients	Genotype/phenotype-guided treatment	Avoids Over- or Under-Treatment	Standardized testing, health insurance coverage

 3.3 The Powerful Complement to siRNA Small Nucleic Acids: Liver-Targeted Lipid-Lowering and Ultra-Long-Acting Advantages

 The rise of small interfering RNA (siRNA) technology in the field of metabolic diseases provides a crucial technological complement to the GLP-1-dominated metabolic drug ecosystem. Represented by GalNAc-modified siRNAs (such as Inclisiran and Lepodisiran), the once-every-six-month dosing regimen of these drugs is redefining the long-term management model for metabolic diseases.

 3.3.1 Latest Clinical Data on Targets Such as PCSK9 and Lp(a), and the Value of Six-Monthly Dosage in Improving Adherence

 ADA 2026 will showcase the latest advancements in nucleic acid therapeutics for metabolic and cardiovascular diseases, with core pipelines focused on three target classes:

 ① PCSK9 siRNA (Inclisiran, Novartis): Already approved by the FDA, administered via subcutaneous injection every 6 months, with an LDL-C reduction of approximately 50–55%. New findings at ADA 2026 will focus on hard data regarding cardiovascular composite endpoints from the combination regimen of GLP-1 RA for weight loss plus Inclisiran for LDL-C reduction, as well as its role in patients with type 2 diabetes at high cardiovascular risk.

 ② Lp(a) siRNA (Lepodisiran, Eli Lilly; Zerlasiran, Silence Therapeutics): Lp(a) is an independent genetic risk factor for cardiovascular disease; approximately 20% of the population has persistently elevated Lp(a) levels due to genetic mutations, and there are currently no approved targeted therapies.Phase II data for Eli Lilly’s Lepodisiran show Lp(a) reductions of over 90%; the 2026 American Diabetes Association (ADA) meeting will present updated data specifically for the subgroup of patients with type 2 diabetes and high Lp(a).

 ③ ANGPTL3 siRNA (Zodasiran, Alnylam): By silencing ANGPTL3, this approach achieves a triple reduction in triglycerides, LDL-C, and Lp(a), offering unique value for patients with diabetic hyperlipidemia. The full Phase II data to be presented at ADA 2026 will be a key highlight.

 Table 3-5: Preview of Key Data for the ADA 2026 Nucleic Acid Drug (siRNA) Pipeline in the Metabolic Field

siRNA Target/Product	Company	Dosage Frequency	Key Efficacy Endpoints	Expected Updates at ADA 2026
PCSK9/Inclisiran	Novartis	Every 6 months	~50% reduction in LDL-C	Cohort data from patients with T2D and cardiovascular risk
Lp(a)/Lepodisiran	Eli Lilly	Every 6 to 12 months	Lp(a) reduction >90%	Data from the T2D + high Lp(a) subgroup
Lp(a)/Zerlasiran	Silence Therapeutics	Every 6 months	Approx. 80% reduction in Lp(a)	Phase II full data
ANGPTL3/Zodasiran	Alnylam	Quarterly/Every six months	Reduction in TG, LDL, and Lp(a)	Phase II Full Data

 The Deep Commercial Significance of Adherence Advantages: Clinical data show that the 12-month treatment retention rate for Inclisiran exceeds 90%, far surpassing that of statins (approximately 50–60%) and PCSK9 inhibitors (approximately 60–70%). High adherence translates to better real-world outcomes, which will serve as a key bargaining chip for nucleic acid drugs in insurance negotiations.

 3.3.2 Roadmap for Combination Therapy Design: GLP-1 Platform + Nucleic Acid Drugs

 Combination therapy with GLP-1 RAs and siRNAs represents the future direction of metabolic disease management—these two classes of drugs address the core issues of metabolic syndrome from complementary perspectives:

 ① Advantages of GLP-1 RAs: Systemic weight loss (fat reduction → reduced inflammation → improved insulin resistance), protection against cardiovascular MACE, and glycemic control, making them suitable for metabolic reprogramming.

 ② Advantages of siRNA: Precise silencing of specific disease-causing genes (PCSK9, Lp(a), ANGPTL3), long-term stable reduction of single lipid/protein targets, independent of patient daily medication adherence, suitable for precise blocking of genetic risks.

 ③ Synergistic value of the combination: In high-risk type 2 diabetes patients, GLP-1 RAs address fundamental metabolic issues, while siRNA addresses hereditary cardiovascular risk factors; the two do not overlap and are not antagonistic, theoretically offering additive benefits for cardiovascular endpoints.

 Table 3-6: Roadmap for the Design of GLP-1 RA + Nucleic Acid Drug Combination Therapy

Combination Regimen	GLP-1 Component	siRNA Component	Target Population	Expected Cumulative Cardiovascular Benefits
Dual Management of Weight Loss and LDL-C	Sema/Tirz	Inclisiran	T2D + Obesity + High LDL-C	Estimated 40–50% reduction in MACE (hypothetical)
Weight Loss + Targeted Lp(a) Inhibition	Sema/Tirz	Lepodisiran/Zerlasiran	T2D + Obesity + Hereditary Hyper-Lp(a)	Reduces Lp(a)-associated risk of myocardial infarction
MASH + Triple Lipid-Lowering Therapy	Tirz (SURMOUNT-MASH)	Zodasiran (ANGPTL3)	MASH + Diabetic Hyperlipidemia	Triple Improvement in Liver Fibrosis, Dyslipidemia, and Cardiovascular Health
Comprehensive Metabolic Syndrome Protocol	Triple-target peptide (in development)	PCSK9 + Lp(a) siRNA combination	High-risk patients with metabolic syndrome	Theoretically Maximum Cardiovascular Benefit

 Action Recommendations (CROs/Platform Service Providers): Preclinical evaluation of GLP-1 + siRNA combination therapies requires capabilities in both peptide PK/PD modeling and nucleic acid tissue distribution (quantitative RT-PCR for mRNA silencing rate detection). We recommend engaging with R&D teams of nucleic acid drug development pipelines during ADA 2026 to discuss needs for joint evaluation services, and proactively establishing one-stop preclinical evaluation capabilities for peptide + nucleic acid combination strategies.

4.0 Practical Conference Strategy (bio international 2026): Avoiding Pitfalls and Planning a High-Value Itinerary in a 12,000-Person Venue

 Given the scale of the ADA Scientific Sessions, attending without a strategy is tantamount to wasting time and money. This chapter provides a systematically designed framework to maximize conference efficiency, helping attendees achieve three key objectives—information gathering, networking, and decision support—within four days.

 4.1 Agenda Screening Framework: How to Identify High-Value Oral Sessions and Late-Breaking Abstracts

 ADA Scientific Sessions publishes over 1,500 abstracts annually, along with dozens of panel discussions, satellite symposia, and corporate presentations—an information overload far exceeding any individual’s capacity to process. Below is an agenda screening framework tailored for biopharma business development (BD) and R&D professionals: GLP-1 clinical development

 ① Top Priority: Late-breaking Clinical Trials: These abstracts are submitted after the regular abstract deadline and typically represent the most significant clinical data of the year. ADA 2026 is expected to feature 25–40 late-breaking abstracts; you should pre-read all of them and selectively attend the oral presentations.

 ② Second Priority: Oral Presentations: With approximately 300–400 oral sessions in total, select 3–5 high-priority sessions for each of your core areas of interest to form the backbone of your personal schedule.

 ③ Third Priority: Distinguished Lectures & Named Lectures: These invited talks by leading scientists and clinical key opinion leaders (KOLs) are the best source for the latest theoretical frameworks and long-term visions in the field, offering immense value for strategic decision-making.

 ④ Fourth Priority: Poster Sessions: The poster area has the highest density of data but varies in quality. It is recommended to quickly scan relevant topic areas during downtime each day, focusing on the first author’s institution and data charts.

 Table 4-1: ADA 2026 Agenda Type Prioritization Framework

Agenda Type	Estimated Quantity	Priority	Recommended Time Allocation	Optimal Utilization Strategy
Late-breaking abstracts	25–40	★★★★★	Pre-read all abstracts; listen to 30–50% of the oral presentations	Identify intersections with company strategy in advance
Oral Session	300–400	★★★★	Select 3–5 per topic, for a total of 15–25	Pre-screen using abstracts; attend only those with high-quality data
Distinguished Lecture	10–20	★★★★	At least one per day	Document KOLs’ assessments of the field’s direction
Poster Session	1,000+	★★★	Scan for 30 minutes each in the morning and evening	Focus on first-author institutions and key charts
Corporate Satellite Sessions	30–50 sessions	★★★★	Select 5–8 of the most relevant	Get Pipeline data and BD signals
ADA Symposium Special Feature	50–80 sessions	★★★	Select 1–2 sessions in your core focus area	Gain a comprehensive understanding of a specific therapeutic area

 Practical Tip: We recommend downloading the official ADA app two weeks before the event and using the priority framework above to create your personal session schedule—fill in the morning, afternoon, and evening slots for each of the four days with your top picks and alternatives to ensure you won’t be left with nothing to do if a session is full.

 Quick Screening Tips for Late-Breaking Abstracts:

 ① Focus on the abstract’s primary endpoints and sample size—large-sample, positive Phase III results are market-moving data; small-sample, exploratory Phase II abstracts have limited value.

 ② Pay attention to sponsors—abstracts sponsored by Eli Lilly, Novo Nordisk, Boehringer Ingelheim, MSD, and Alnylam typically contain market-sensitive data.

 ③ Create a pre-set exclusion list—identify 2–3 areas you do not plan to pursue in depth during this conference (e.g., medical devices, purely basic science) to avoid wasting time on them.

 4.2 Poster Sessions and Networking Hotspots: Which Areas Are Most Worth Spending Time In

 The layout of the Ernest N. Morial Convention Center typically divides the exhibition area into multiple halls, with abstracts grouped by theme. For biopharma BD and R&D professionals, the following areas offer the highest value for in-depth exploration:

 ① GLP-1 & Incretin Novel Therapies Poster Session: This area features the largest concentration of preclinical and early-clinical data on multi-target peptides, offering firsthand insights into the competitive landscape of next-generation GLP-1 therapies. We recommend bringing business cards and directly approaching the first or corresponding authors of posters that pique your interest for in-person discussions.

 ② Novel Drug Delivery & Technology Poster Area: This is the hub for the latest data on novel technology platforms such as PDC, AOC, and nucleic acid delivery, making it the most efficient venue for evaluating technology collaboration opportunities.

 ③ Exhibition Hall: With over 200 exhibiting companies, we recommend pre-planning a list of 30–40 must-visit booths, focusing on gathering information about new product line announcements and changes to collaboration terms.

 ④ Networking Reception: Officially organized events by ADA, such as the Welcome Reception and Young Investigator Meeting, provide prime opportunities for in-depth dialogue with Key Opinion Leaders (KOLs) and senior management—far more efficient than chance encounters in the conference hall corridors.

 Table 4-2: ADA 2026 Networking Hotspots and Event Guide

Area/Event	Best Time	Target Outcomes	Preparation Checklist
GLP-1 Peptide Poster Area	Day 1/2, 9:00–11:00 AM	Overview of the Latest Multi-Target Technology Posters	Keywords: Triple agonist/PDC/GLP-1R biased
Nucleic Acid Delivery Poster Session	Day 2/3, 3:00–5:00 PM	siRNA/GalNAc/LNP Data	Keywords: GalNAc-siRNA/Liver-targeted/PCSK9/Lp(a)
Corporate Exhibition Area	Day 1/2, 11:00 AM–12:00 PM (Less Crowded)	Company New Product Lines + Collaboration Terms	List of 10–15 Target Companies
Welcome Reception	Day 1, 6:00–8:00 PM	Networking with KOLs and executives from major pharmaceutical companies	Prepare a 1-minute elevator pitch (company value proposition)
Company Breakout Sessions	Day 0/4 (All day before/after the conference)	Full Pipeline Data Presentation	Register early—seats are limited
Joint ADA/ASCO Session	Morning of Day 2 (Tentative)	Latest Insights from the Metabolism-Oncology Interface	Preview the Background of the ASCO GI Cohort Study

 4.3 A Commercial Capital Perspective: Highlights of Satellite Symposia, Corporate Presentations, and Business Development Matchmaking (Eli Lilly, Novo, BI, MSD, etc.)

 Satellite symposia are among the most commercially valuable event formats at ADA. Unlike official academic sessions, satellite symposia are sponsored by pharmaceutical companies and typically showcase the latest commercial data, guidance on guideline implementation, and previews of next-generation products, making them the public information source closest to corporate strategic planning.

 Predictions for Key 2026 ADA Satellite Symposia (Based on the 2025 Model):

 ① Eli Lilly Satellite Symposium: Expected to highlight the full data package for tezelepatide in MASH and HFpEF, as well as interim signals from the Orforglipron Phase III trial. Lilly typically schedules its satellite symposium for the evening of the first day of the conference, when attendance is highest.

 ② Novo Nordisk Satellite Symposium: Full data from the somatropin FLOW trial (CKD) and an analysis of updates to the Standards of Care, along with the latest progress on next-generation multi-target peptides (e.g., Cagrisema).

 ③ Boehringer Ingelheim Satellite Symposium: MASH data for BI 456906 (GLP-1/Glucagon dual-target) and an integrated analysis of SGLT2 inhibitor (empagliflozin) data in new indications.

 ④ MSD/Merck Satellite Session: Full MASH Phase II data for Efinopegdutide (GLP-1/Glucagon).

 ⑤ Alnylam/Silence Therapeutics: Ultra-long-term follow-up data on nucleic acid therapeutics for metabolic diseases (5-year safety of Inclisiran), and a dedicated analysis of Lp(a)-targeted siRNA in high-risk T2D patients.

 Table 4-3: Assessment of the Anticipated Value of Major Pharmaceutical Companies’ Satellite Sessions for BD/CRO Collaboration

Company	Expected Satellite Symposium Topics	BD Engagement Value	Signal of Demand for CROs
Eli Lilly	Tirz MASH/HFpEF Full Data + Orforglipron Teaser	Extremely High	Increased demand for oral GLP-1 PK/ADME studies
Novo Nordisk	Sema FLOW CKD Full Data + Cagrisema Progress	Very high	Demand for evaluation using a combined nephrology and cardiovascular model
Boehringer Ingelheim	BI 456906 MASH Data + New SGLT2 Indications	High	Evaluation of GLP-1/Glucagon Dual-Target Peptide Synthesis
MSD/Merck	Efinopegdutide MASH Phase II Full Data	High	Evaluation Platform for Liver-Targeting of Dual-Target Peptides
Alnylam	Inclisiran 5-Year Safety Data + Lp(a) siRNA Progress	High	siRNA In Vitro Transfection Efficiency + Hepatocyte Targeting Evaluation
Amgen	Long-term Weight Loss Follow-up for AMG 133 (bispecific)	Moderate to high	Bispecific Antibody CMC + In Vitro Binding Affinity Evaluation

 Action Recommendations (BD Team): We recommend scheduling appointments with the heads of the BD/Alliance Management teams at the above companies via the ADA website or LinkedIn 1–2 weeks prior to the conference. This will elevate casual conversations during the event from cold outreach to scheduled meetings. Even a 5–10-minute hallway conversation can yield 3–5 times more information if a connection has been established in advance.

5.0 New Orleans Conference Survival Guide: Your bio international 2026 Companion: Make Your ADA Trip Efficient and Comfortable

 New Orleans (nicknamed “The Big Easy”) is one of the most culturally distinctive cities in the United States, renowned for its French Creole architecture, jazz, Cajun cuisine, and Mardi Gras. June in New Orleans marks the height of summer, with hot and humid weather; however, this is not an issue inside the fully air-conditioned convention center.This chapter provides a practical survival guide for biopharmaceutical professionals to ensure your conference experience is not only productive but also smooth and comfortable.

 5.1 Venue Layout, June Weather Tips, High-Speed Internet, and Charging Tips

 Venue Navigation:

 ① The Ernest N. Morial Convention Center is one of the largest contiguous single-level exhibition spaces in North America, with a total exhibition area exceeding 1 million square feet. The venue is divided into multiple halls (Halls A–J, etc.), and walking between them may take 10–15 minutes. We recommend setting aside one hour on Day 0 (the afternoon before the conference) to walk through the entire venue, locate the areas you need most, and avoid getting lost during the morning rush on Day 1.

 ② Limitations of On-Site Mobile Navigation: GPS signals are weak inside large convention centers. We recommend using the venue map feature in the official ADA app or printing out the official floor plan to carry with you.

 ③ Peak-Hour Avoidance Strategy: The corridors and exhibition areas are most crowded daily from 8:30–9:30 AM and 12:00–1:00 PM. We recommend scheduling lower-priority poster scans during these times and scheduling high-priority presentations and meetings during the off-peak hours of 1:30–5:30 PM.

 June Weather Considerations:

 ① New Orleans’ average June temperature is 30–34°C, with humidity above 80%; the outdoor heat index can exceed 40°C. If the walk from your hotel to the venue takes more than 5 minutes, we recommend using Uber/Lyft or the conference’s free shuttle to avoid excessive sweating outdoors, which could affect your energy levels for the rest of the day.

 ② The air conditioning in the venue is typically set quite low (around 20–22°C), and the temperature difference between outdoors and indoors exceeds 10°C. We recommend carrying a light jacket or windbreaker with you.

 ③ It is recommended to drink more than 2.5 liters of water daily. While there are usually free water stations inside the venue, bringing your own large bottles of mineral water is a wise move.

 High-Speed Internet and Charging:

 ① The official venue WiFi may only reach speeds of 3–5 Mbps during peak hours. We recommend purchasing a local U.S. SIM card (T-Mobile/AT&T prepaid cards, $30–50 for 30 days, 20GB+ of high-speed data) as a backup network.

 ② Charging: Bring 2–3 power banks (total capacity >30,000 mAh) and a multi-port GaN charger, as outlet availability is limited and highly competitive within the venue.

 ③ Audio and Video Recording Guidelines: Most venues allow personal phone audio recording but prohibit video recording. We recommend using a transcription app (such as Otter.ai) for automatic transcription, which can increase post-event organization efficiency by 3–5 times.

 Table 5-1: New Orleans Conference Logistics Checklist

Item	Specific Recommendations	Cost Estimate
Transportation	Conference shuttle + Uber; driving is not recommended (parking fees $30–50/day)	$50–100/day
Accommodations	Conference-recommended hotels (5–10-minute walk); book 3 months in advance	$200–350 per night
Local SIM card	T-Mobile/AT&T 30-day prepaid	$30–50
Power bank	2 x 30,000mAh + multi-port GaN charger	Bring your own
Jacket/Windbreaker	Lightweight mid-layer for dealing with strong indoor air conditioning	Bring your own
Business cards	Paper business cards (100 or more) + digital business card app (e.g., HiHello)	Printing costs approx. $20–50
Abstract booklet (optional)	PDF version available on the ADA website; print and bring high-priority abstracts	$10 for printing

 5.2 Recommended Social Hotspots: Curated Business Cafés and Louisiana Specialty Restaurants

 New Orleans’ culinary culture blends French, Spanish, African, and Caribbean culinary traditions to create the unique flavors of Creole and Cajun cuisine. Below are recommendations for business networking venues and restaurants curated specifically for biopharmaceutical professionals:

 Recommended Business Cafés/Workspaces:

 ① CC’s Community Coffee (multiple locations): A local Louisiana specialty coffee chain featuring locally roasted beans and reliable WiFi. Ideal for organizing notes between meetings or holding 1–2-hour business discussions, with affordable prices ($4–6 for coffee).

 ② Hyatt Regency Lobby Bar: As one of the main conference hotels, the lobby bar is an ideal venue for informal business development meetings. During afternoon tea hours (2:00–5:00 PM), foot traffic is moderate, making it suitable for in-depth discussions; a single drink costing $12–18 allows you to occupy a seat for several hours. biotech partnering

 Table 5-2: Recommended Business Restaurants for Conference Attendees in New Orleans

Restaurant Name	Specialty	Price Range (per person)	Ideal Occasion	Reservation Tips
Antoine’s Restaurant	Founded in 1840, New Orleans’ oldest French Creole restaurant	$80–120	Dinners for VIPs / Celebrations	Reserve 1–2 weeks in advance
Galatoire’s	A century-old institution, famous for its signature dish, Trout Almondine	$70–100	Mid-to-high-end formal business dinners	Book 2 weeks in advance for Friday/Saturday
Commander’s Palace	A Garden District classic, Jazz Brunch (weekends)	$60–100	Formal Business Luncheon for Negotiations	Reserve 1 week in advance
Cochon	Cajun-style, featuring local pork	$40–70	Casual Business Networking Dinner	Reserve 3–5 days in advance
Cafe Du Monde	Open 24 hours, French-style beignets + coffee with milk	$10–15	Relax after the event / Casual socializing	No reservation required; drop in anytime
Compere Lapin	Caribbean-Creole fusion, Michelin-recommended	$50–80	Small group celebrations / Special gatherings	Book 1 week in advance

 Practical Tip: During the conference (June 5–8), New Orleans restaurants will experience a surge in conference-goers. We strongly recommend completing all essential restaurant reservations before your trip; otherwise, you may face 1–2 hour wait times or be unable to secure a table on the day of your visit. Both OpenTable and Resy support online reservations for New Orleans restaurants; we recommend using these apps.

 5.3 Post-Conference Action List: Clinical Practice, R&D Decision-Making, and Team Knowledge Map Templates

 The true value of attending the conference lies not in the event itself, but in how you translate the information gained into organizational action. Below are post-conference action list templates tailored to different roles; we recommend drafting them on your return flight:

Tasks to be completed within 24 hours (on the plane/during the return trip):

 ① Organize notes from the day’s sessions and transcribe recordings, distilling 1–3 key takeaways from each presentation (limited to 200 words to ensure conciseness).

 ② Categorize business cards received into three groups: “Follow up immediately,” “Follow up within 1 month,” and “Archive.” For the “Follow up immediately” category, send a LinkedIn connection request and a brief email within 24 hours of returning.

 ③ Record any surprising insights that exceeded expectations (data or perspectives that caused you to revise a pre-existing judgment); these are often the most strategically significant insights.

 Tasks to complete within 1 week:

 ① Complete the official conference report (recommended template: 1-page Executive Summary + 3–5 pages of detailed sector analysis) and send it to management and relevant teams.

 ② Update the company’s competitor pipeline database: Enter the new data released by ADA into the existing database.

 ③ Assess the need to adjust the company’s R&D/service product lines: Based on the new ADA data, is there a specific direction that requires accelerated development?

 Table 5-3: Post-Conference Action List Template

Action Date	Action Item	Recommended Responsible Party	Deliverables
Within 24 hours	Organize notes + Extract key information	Attendee	200-word summary per presentation
Within 24 hours	Business card/contact categorization + immediate follow-up	Attendee	LinkedIn/Email Send Log
Within 1 week	Drafting of official conference report	Attendee + BD Manager	1–5-page report
Within 1 week	Pipeline database update	Research/BD Team	Updated Competitive Intelligence Database
Within 1 week	Internal Presentation (30–60 minutes)	Presentation to the team	PPT Presentation
Within 1 month	Follow-up BD conversations (scheduled meetings)	BD Team	Meeting calendar + agenda preparation
Within 1 month	Assessment Report on R&D Direction Adjustments	VP of R&D + BD Manager	Strategic Adjustment Memo

 Building a Team Knowledge Map: If multiple members of your team are attending (across different tracks), we recommend holding a one-hour internal knowledge-sharing session within one week after the conference. Each participant should share 3–5 of their most valuable takeaways, and use a shared document to build an ADA 2026 Team Insights Knowledge Base for easy future reference and citation.The value of this knowledge base will grow over time—reviewing these records 12 months later will allow you to assess which predictions were accurate and which signals were underestimated, providing a more precise foundation for prioritizing information for the next ADA conference.

6.0 Conclusion: bio international 2026 and ADA 2026—Witnessing the Dawn of the Second Half of the Grand Convergence of Precision and Systems Medicine in Biopharmaceuticals

 After the in-depth analysis in the previous five chapters, standing at the threshold of ADA 2026, we can clearly see the historical significance of this conference: it is not merely an academic annual meeting, but a historic stage marking a pivotal juncture in the global biopharmaceutical industry’s transition from single-disease targeted therapy to the grand convergence of systemic precision metabolic medicine.GLP-1, peptides, small molecules, and nucleic acids—these four molecular platforms are converging toward a common goal from different dimensions, leveraging their unique mechanistic advantages: to systematically address the root causes of modern lifestyle diseases (metabolic syndrome, cardiovascular disease, cancer, and neurodegenerative diseases). metabolic disease conference

 6.1 Long-Term Challenges and Reflections on Sustainable Innovation (Safety, Adherence, Accessibility)

 The rapid rise of GLP-1 peptides and metabolic drugs has obscured several long-term challenges, and ADA 2026 will address these issues with a responsible academic approach:

 ① Long-tail safety risks: Gastrointestinal side effects of GLP-1 RAs are well-documented, but safety data for long-term use (>5 years) is still accumulating. Of particular concern is the issue of muscle loss—the proportion of lean body mass lost during weight loss may reach 20–30% in some patients, posing a risk of falls and fractures in elderly patients.ADA 2026 will discuss how to address this issue through protein supplementation, exercise interventions, and next-generation molecules targeting adipose tissue reduction.

 ② Systemic challenges with adherence: Even for injectable GLP-1 RAs, the 12-month treatment retention rate is only about 30–40%, and weight often rebounds rapidly after discontinuation (data from the SURMOUNT-5 extension trial). This implies that the treatment of metabolic diseases is inherently a matter of chronic, ongoing management rather than a one-time cure—similar to the lifelong management model for hypertension and hyperlipidemia.

 ③ Global Inequality in Access: The monthly cost of Ozempic/Wegovy in the U.S. is approximately $900–1,300 (before insurance discounts). For the more than 1 billion obese or overweight people worldwide (most of whom live in low- and middle-income countries), current price levels mean these drugs are effectively limited to wealthy nations.ADA 2026 will discuss generic drug pathways, regulatory frameworks for biosimilars, and the feasibility of localized production in emerging markets.

 Table 6-1: Overview of Long-Term Challenges and Solutions for GLP-1 and Metabolic Drugs

Long-Term Challenges	Current Status	Expected Discussions at ADA 2026	Solutions (Short/Medium/Long Term)
Sarcopenia	Observed, under investigation	Combination of protein + exercise + novel molecular interventions	Short-term: Exercise prescriptions; Medium-term: New muscle-preserving targets (e.g., myostatin)
Rebound after discontinuation	SURMOUNT extension data has confirmed	Discussion of lifelong treatment models	Short-term: Tapering and maintenance; Medium-term: Intermittent treatment regimens
GI side effects	Known; some patients cannot tolerate	Dose titration + antiemetic combination strategy	Short term: Slow titration; Medium term: Modified formulations
Global Accessibility	Extremely low (high price)	Discussions on generic drug pathways and biosimilar regulatory frameworks	Mid-term: Patent expiry 2026–2028; Long-term: Localization in emerging markets
Long-term cardiac safety (>10 years)	Data not yet complete	Subgroup analysis of early data from a 10-year cohort	Long-term: Long-term follow-up data to mature in the 2030s

 Key Conclusion: Understanding these long-term challenges holds direct strategic value for business development and R&D teams. Every gap in safety, adherence, and accessibility represents an R&D opportunity—safer formulations, more adherent delivery methods, and lower-cost manufacturing technologies will become the differentiating competitive dimensions in the GLP-1 space over the next five years.

 6.2 Global Regulatory and Market Implications for Asian Companies

 For biopharmaceutical companies based in China or Asia (whether pharmaceutical firms, CROs, or service providers), the signals conveyed by ADA 2026 hold particular significance from an Asia-Pacific perspective:

 ① The window of opportunity in China’s GLP-1 market: Currently, approved GLP-1 receptor agonists (GLP-1 RAs) in China include liraglutide, dulaglutide, and injectable semaglutide; however, the timeline for the launch of oral semaglutide and tizepatide in China has not yet been fully confirmed.Domestic Chinese pharmaceutical companies (such as Huadong Medicine’s benarlutide and Bori Pharma’s oral GLP-1 agonist) have significant room to catch up during this window of opportunity. Data from ADA 2026 will help domestic companies assess the feasibility of differentiated positioning.

 ② Differences in metabolic phenotypes among Chinese patients: The metabolic phenotypes of Chinese patients with type 2 diabetes and obesity differ significantly from those of Western populations—at the same BMI, Chinese individuals have a higher proportion of visceral fat, earlier decline in pancreatic beta-cell function, and a different prevalence of high Lp(a). This implies that GLP-1 efficacy data established in Western populations cannot be directly extrapolated to Chinese patients and require dedicated bridging studies.

 ③ Alignment with NMPA Regulatory Pathways: During ADA 2026, representatives from international regulatory agencies (FDA, EMA, PMDA) will participate in panel discussions. Their latest perspectives on topics such as cross-disciplinary metabolic-oncology trial design, biosimilar regulatory frameworks, and bioequivalence (BE) standards for oral GLP-1 RAs will provide valuable insights for assessing potential follow-up regulatory policies by the NMPA.

Table 6-2: Comparison of GLP-1 RA Markets in the West vs. China/Asia and Implications for Local Companies’ Strategies

Dimension	Current Status of Western Markets	Characteristics of the Chinese/Asian Market	Implications for Local Companies
Patient BMI Threshold	A BMI of 30 or higher is classified as obesity; a BMI of 27 or higher may be eligible for treatment if complications are present	In China, obesity is defined as a BMI of 28 or higher, and overweight as 24 or higher	The rationality of prescribing for patients with low BMI requires support from local data
Metabolic Phenotypes	Predominantly subcutaneous fat	Higher proportion of visceral fat (for the same BMI)	Evidence supporting visceral fat reduction as a primary efficacy endpoint
Pattern of Complications	High burden of cardiovascular disease	High incidence of diabetic nephropathy and early-onset NAFLD	Prioritized development of kidney protection and MASH indications
Health insurance coverage	Included in insurance coverage in multiple countries (excluding the weight loss indication)	China’s health insurance does not yet cover the weight loss indication for GLP-1 RAs	Domestic pricing strategies and pathways for health insurance access negotiations
Local Competitive Landscape	Eli Lilly/Novo Nordisk duopoly	Rapid growth of domestic GLP-1 pipelines (20+ pipelines)	First-mover advantage in differentiated segments (oral/triple-target/PDC)

 Key Takeaway: For Asian attendees, ADA 2026 is not merely a venue for data collection, but also an opportunity to develop a global perspective and calibrate localized strategies. Every global dataset should be scrutinized with the question: What are the results for Chinese patient subgroups? If none exist, this represents a research gap—and a competitive opportunity.

 6.3 Conclusion: How to Translate ADA Insights into True Competitive Advantage for 2026–2027

 The ultimate goal of attending the ADA Scientific Sessions is not merely to gather information, but to transform that information into insights, convert those insights into action, and turn that action into a competitive advantage.

 For professionals in the biopharmaceutical industry, the core insights from ADA 2026 can be distilled into the following five framework-based judgments:

 ① The next frontier for GLP-1 is not weight loss, but systemic organ protection: Data on the protection of the heart, kidneys, liver, and even the nervous system is maturing, meaning the indication matrix will expand from weight loss/glucose control to the broader field of chronic disease prevention. Over the next five years, teams that position GLP-1 as an integrated solution for metabolism and organ protection will hold a structural advantage in BD negotiations and market positioning.

 ② Multi-target does not mean more complex; it means more precise: Data on the three targets—GLP-1, GIP, and glucagon—do not simply follow an “addition is better” principle, but rather demonstrate targeted mechanistic advantages in specific patient populations. Future product differentiation will be based on precise target combinations and precise patient stratification, rather than merely the number of targets.

 ③ The advent of the oral era will reshape the entire industry chain: Once oral GLP-1 RAs succeed, they will not only transform prescribing patterns but also alter CMC/supply chain operations, generic drug timelines, and methods for collecting patient behavior data. Proactively establishing preclinical and clinical development service capabilities for oral small-molecule GLP-1 agents is a priority strategic option for the next three years.

 ④ Nucleic acid therapeutics are the ideal long-acting partners for GLP-1: The target specificity and ultra-long duration of action provided by siRNA/ASO are highly complementary to the systemic metabolic remodeling effects of GLP-1. The synergy between these two technologies will become the standard treatment regimen for high-risk patients with metabolic syndrome; the window for establishing nucleic acid therapeutic platform capabilities is 2024–2027.

 ⑤ True Competitive Advantage Stems from Rapid Learning + Systematic Integration: ADA publishes hundreds of studies annually; competitive advantage lies not in whether one attends the conference, but in whether one has established a systematic capability to rapidly integrate new data into corporate strategy, R&D roadmaps, and business development (BD) messaging. Building a team knowledge map, regularly updating competitive intelligence databases, and translating conference insights into actionable R&D decisions are the key pathways to transforming investment in ADA into genuine competitive advantage.

 Table 6-3: Matrix of Five Key Framework Assessments and Action Implications from ADA 2026

Framework Assessment	Action Implications for R&D Teams	Action Implications for the BD Team	Time Window
GLP-1 Organ Protection	Develop multi-organ protection and multi-endpoint evaluation capabilities	Update Indication Messaging to Include Kidney/Liver/Heart	2026–2027
The Era of Precision Multi-Target Therapy	Establish an evaluation platform for target combinations and patient stratification models	Differentiate as a CRO specializing in metabolic precision medicine	2026–2028
Rise of Oral Small-Molecule GLP-1 Agonists	Expanding Services for Oral PK, Bioavailability, and Metabolic Stability Evaluation	Develop a one-stop preclinical service package for oral GLP-1	2026–2027: Critical Window
Synergy with Nucleic Acid Drugs	Establishing Capabilities for siRNA Liver Targeting and Silencing Efficiency Evaluation	Proactively engage with the BD teams at Alnylam and Eli Lilly’s nucleic acid divisions	2025–2027
Systematic Learning Capabilities	Establish an annual conference attendance standard operating procedure (SOP)	Systematize conference insights into BD messaging updates and market analysis reports	Continuous Iteration

 In June 2026, New Orleans will witness a historic convergence of metabolic medicine and precision therapy. Whether attending the ADA for the first time or having attended ten times before, the density of information and strategic significance of this conference warrant more dedicated preparation, deeper exploration, and more effective implementation than any previous edition. Go with questions and return with answers—this is the only way to gain a true competitive edge from the ADA.

7.0 Frequently Asked Questions (FAQ): bio international 2026 Edition

 Below are the most frequently asked questions from attendees of the ADA Scientific Sessions 2026:

 Q1: What are the key highlights of the ADA 2026 Scientific Sessions?

 The three key highlights of this year’s ADA:

First， Phase III clinical data on GLP-1 multi-target peptides (dual- or triple-target) for new indications such as MASH, CKD, and obesity-related cancers;

Second， Latest Phase III updates on oral non-peptide GLP-1 RAs (represented by Eli Lilly’s Orforglipron), marking a historic milestone in the dawn of the oral era;

Third， A dedicated session on nucleic acid therapeutics (siRNA/ASO) in the field of metabolic diseases, including the latest long-term follow-up data for PCSK9 siRNA (Inclisiran) and Lp(a) siRNA (Lepodisiran).

 Q2: Where will the ADA 2026 conference be held? When will it take place? How do I register?

 The ADA 2026 Scientific Sessions will be held from June 5 to 8, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana (LA).Official website: https://professional.diabetes.org/scientific-sessions. Registration is available on the official website. ADA members are eligible for registration discounts ranging from $200 to $400. We recommend registering 2–3 months in advance to take advantage of early-bird discounts and to book your hotel at the same time (we recommend the conference-recommended hotel, which is within walking distance of the venue).

 Q3: What new indications for GLP-1 receptor agonists will be discussed at ADA 2026?

 ADA 2026 will highlight clinical data on GLP-1 receptor agonists (GLP-1 RAs) in the following new indication areas:

•  MASH (metabolic-associated steatohepatitis)—96-week fibrosis reversal data for tizepatide, and full Phase II data for BI 456906 and MSD’s efinopegdutide;
•   Chronic Kidney Disease (CKD) — Full data from the FLOW trial; expected upgrade to a Class 1A recommendation in the Standards of Care;
•  Heart Failure with Preserved Ejection Fraction (HFpEF) — Follow-up data from the SUMMIT trial and guideline updates;
•   Obesity-related cancers (exploratory) — In-depth discussion of mechanisms based on the ASCO GI cohort study and early trial safety readouts;
•  Neurodegenerative Diseases (Exploratory) — Preliminary data from the EVOKE trial (somalupant + Alzheimer’s). Each indication represents a potential market opportunity worth billions of dollars.

 Q4: Which nucleic acid therapeutics (siRNA/ASO) will be featured at ADA 2026? What does this mean for CROs?

 ADA 2026 will feature a dedicated session on nucleic acid therapeutics, with key pipelines including:

 Novartis’ Inclisiran (PCSK9 siRNA, administered every 6 months, reduces LDL-C by approximately 50%,5-year long-term safety data), Eli Lilly’s Lepodisiran (Lp(a) siRNA, administered every 6–12 months, >90% reduction in Lp(a)), and Alnylam’s Zodasiran (ANGPTL3 siRNA, triple reduction in TG, LDL, and Lp(a), with full Phase II data).

 For CROs and pharmacodynamic service providers, this means: demand for siRNA in the field of metabolic diseases is expanding from cardiovascular conditions to nephropathy/MASH. To meet this emerging demand, providers must possess capabilities for evaluating in vitro transfection efficiency of GalNAc-siRNA in hepatocytes, quantitative detection of mRNA silencing rates, and one-stop preclinical evaluation of combined GLP-1 peptide + siRNA regimens.

 Q5: As a representative of Chinese/Asian biopharmaceutical companies, what is the core strategic value of attending ADA 2026?

For biopharmaceutical companies in China and Asia, the core strategic value of ADA 2026 lies in four key areas:

•  Early Insights—Gain access to the latest data on next-generation pipelines (oral GLP-1, multi-target peptides, PDC) from industry giants such as Eli Lilly and Novo Nordisk to anticipate shifts in the competitive landscape of the Chinese market;
•  Regulatory Insights — Gaining insight into the latest stances of the FDA and EMA on topics such as cross-indication trial design and biosimilar frameworks, which directly inform predictions regarding the NMPA’s regulatory pathway;
•   BD Connections — Establishing international business development partnerships at the world’s most concentrated hub for metabolic medicine KOLs and industry executives to secure opportunities for licensing and collaborative research; pharma partnering summit
•  Localization Validation — Collect data on Asian subpopulations and insights from specialized discussions to assess the generalizability of Western data to Chinese patients, and identify research gaps specific to Asia as avenues for differentiated research.